This analysis reveals the potential of tertiary lymphoid structures as biomarkers of immunotherapy response in cancer, suggesting new treatment avenues.
TLS represent a promising biomarker for prognosis and immunotherapy response. Standardised evaluation methods and prospective clinical validation are essential to enable their integration into personalised treatment strategies.
No takes yet. Share an insight, caveat, or question.
Medhin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: